Companies › Calico Life Sciences
2 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 2; Genitourinary, Oncology, Metabolic and endocrine; next expected readout Nov 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ABBV-CLS-484 | – | Phase 2 | Autosomal Dominant Polycystic Kidney Disease; Advanced Solid Tumor Cancer | Aug 2029 |
| Fosigotifator | – | Phase 1 | Vanishing White Matter Disease | Nov 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04777994 | ABBV-CLS-484 | Phase 1 | Advanced Solid Tumor Cancer | Oncology | Oct 2026 |
| NCT05757141 | Fosigotifator | Phase 1 | Vanishing White Matter Disease | Metabolic and endocrine | Nov 2027 |
| NCT06902558 | ABBV-CLS-484 | Phase 2 | Autosomal Dominant Polycystic Kidney Disease | Genitourinary | Aug 2029 |
No annotated target.
–
Everest Medicines (China) LG Chem Alentis Therapeutics iTeos Therapeutics Shenzhen Kangzhe Biotechnology
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.